| Literature DB >> 31992276 |
Katia Forti1,2, Monica Cagiola3, Martina Pellegrini3, Lucia Anzalone3, Antonella Di Paolo3, Sara Corneli3, Giulio Severi3, Antonio De Giuseppe3.
Abstract
BACKGROUND:Entities:
Keywords: Affinity chromatography; Atoxic rBacCPA250–363H6; Clostridium perfringens; L21 leader sequence; Recombinant vaccines
Year: 2020 PMID: 31992276 PMCID: PMC6986089 DOI: 10.1186/s12896-019-0597-4
Source DB: PubMed Journal: BMC Biotechnol ISSN: 1472-6750 Impact factor: 2.563
Primer sequences of the recombinant truncated rBacCPAH6 proteins. The restriction sites and the start codons are underlined with a solid line, in bold the consensus leader sequences
| Primers | Nucleotide sequences |
|---|---|
| rBacCPA 279- | 5’-AAGA |
| rBacCPA 279 | 5’-AAGA |
| rBacCPA 279 | 5’-TGAT |
| rBacCPA250 | 5’-ATTC |
| rBacCPA 363- | 5’-AAGT |
| rBacCPA 370- | 5’-ACTT |
ain bold= consensus leader sequences
bwith underline= restriction site
cwith underline= start codon
Fig. 1Analysis of the C-terminal fragment rBacCPA279–363H6 with different consensus leader sequences. 7.5 × 106 Sf21 cells were infected in 10 ml of an EX-Cell 420 serum free medium with recombinant virus at a multiplicity of infection (MOI) of 2.0. After 72 h post-infection the infected cells were collected and lysed and the total protein of this preparation was quantified by the Bradford assay. Equal quantity of the cellular lysate of each sample was loaded electrophoresed on 12% SDS-PAGE gels and at the same time both (a) stained with Coomassie blue and (b) analysed in Western blot using an anti-His6-HRP conjugated MAb. Lane 1: rBac CPA279–363H6 without a leader sequence; lane 2: rBacCPA279–363H6 with L21 sequence; lane 3: rBacCPA279–363H6 with Kozaks sequence; lane 4: non-infected Sf21 cells (negative control); lane 5: Sf21 cell infected with recombinant baculovirus containing a target gene His tagged but not related with CPA (His6 positive control); lane 6: protein markers (the molecular weight bands in kDa, are reported on the right). The infections was repeated more than three times and the figure represents the highest-quality picture obtained
Fig. 2Western blot analysis of the C-terminal fragment rBacCPA279–363H6 in different media. Sf21 cells were infected with rBacCPA279–363H6 with L21 sequence in different media and the cellular lysates harvested 72 h post-infection and quantified by the BioRad assay. Equal quantity of the cellular lysate of each sample was loaded electrophoresed on 12% SDS-PAGE gels and simultaneously both (a) stained with Coomassie blue and analysed (b) in Western blot using an anti-His6-HRP conjugated MAb. Lane 1: recombinant protein in Grace’s medium supplemented with 10% FBS; lane 2: recombinant protein in EX-cell 420 serum free medium; lane 3: recombinant protein in HYQ-SFX in serum free medium, lane 4: cellular lysate of Sf21 uninfected cells (negative control); lane 5: protein markers with the molecular weight bands in kDa reported on the right
Fig. 3Schematic representations and analysis via Western blot of the truncated recombinant rBacCPAH6 toxins. a The scheme were drawn approximately on scale, with amino acids numbered according to their positions in the CPA. Leader peptide (amino acids 1–28) were depicted as shown. The deleted forms of rBacCPAH6 were represented by bars. b Equal quantity of the cellular lysate of each sample harvested 72 h post infection, was loaded, electrophoresed on 12% SDS-PAGE gels and stained with Coomassie blue and analysed in Western blot using an anti-His6-HRP conjugated MAb. Lane 1: rBacCPA250–363H6 (approximately 15 kDa); lane 2: rBacCPA279–363H6 (approximately 11 kDa); lane 3: rBacCPA250–370H6 (approximately 16 kDa); lane 4: rBacCPA279–363H6 (approximately 12 kDa); lane 5: cellular lysate of Sf21 uninfected cells (negative control); lane 6: 100 ng of purified rCPB2Δ1–25-His6 (His6 positive control). The protein molecular weight marker is reported
Fig. 4Purification and characterization of truncated recombinant rBacCPA250–363H6. a Coomassie stained 12% SDS-PAGE analysis after Ni-NTA purification. Lane 1: fraction observed on washing the column, after the passage of the recombinant rBacCPA250–363H6; lane 2–7: Elution fractions; lane 8–10: 1 μg, 2 μg and 4 μg of BSA standard; lane 8: Protein molecular weight marker. b Coomassie stained 12% SDS-PAGE analysis after Ni-NTA purification and after the dialysis step in PBS buffer. Lane 1: Elution fractions before the dialysis step (10 μl); Lane 2: Elution fractions after the dialysis step (10 μl); Lane 3: Elution fractions after the dialysis step (1 μl); (c) Immunoblot analysis of the elution fractions performed after Ni-NTA purification using anti-His6-HRP conjugated MAb. Lane1–3: Elution fractions corresponding to lane 2, 3 and 4 of samples in Comassie (a). The protein molecular weight marker is shown on the right
Fig. 5Cytotoxicity of rBacCPA250–363H6 in CaCo-2 cells. Cells were treated as described in the methods section with rBacCPa250–363H6, PLC and culture supernatant of C. perfringens C-5560/18 strain. a The viability of cells, as determined by the MTS assay, after treating cells with indicated concentrations of rBacCPA250–363H6 and PLC toxins and (b) with a serially diluted solution of the supernatant of C. perfringens C-5560/18 strain. The data represent the mean of three independent experiments
Fig. 6In vitro neutralization of the biological activity CPA toxin. Full-length PLC were left untreated or pre-incubated, in the presence of 4 mM CaCl2, with serum obtained from a mouse immunized with the non-toxic rBacCPA250–363H6 and the specifically generated MAb 318F11B7. They were then spotted on TSC agar and incubated overnight at 37 °C. The neutralization of PLC activity results in the absence of an outer zone of hydrolysed phospho-lipid. The positive symbol (+) indicate the presence the activity of the toxin while the negative symbol (−) indicate the absence of the activity of the toxin or its complete neutralization. Recombinant truncated rBacCPA250–363H6 protein untreated did not exhibit any lecithinase activity. Representative image of three independent experiments is shown
Fig. 7Characterization of polyclonal and monoclonal antibodies against rBacCPA250–363H6 by western blotting. The MAbs (section a-d) and PAbs (section e) generated were tested against culture supernatant of the C. perfringens CPA toxin producer. The name of the tested antibody is shown below the corresponding picture. The MW marker is shown on the left. Section a and b: Culture supernatant of C. pefringens strain C-5560/18 (lane 1), culture supernatant of C. septicum, used as a negative control (lane 2), and a mixture of full length PLC and rBacCPA250–363H6 (lane 3). Section c and d: Culture supernatant of C. perfringens strain C-5560/18 (lane 1), culture supernatant of C. septicum, used as a negative control (lane 2), full length PLC (lane 3), and rBacCPA250–363H6 (lane 4). Section e: Rabbit anti-rBacCPA250–363H6 PAbs and anti-PLC (Star Fish): mixture of rBacCPA250–363H6 and PLC (lane 1), different culture supernatants of C. perfringens CPA protein producers (lane 3–5), and culture supernatant of C. septicum, used as a negative control (lane 2). Section f: MAb 318F11B7 tested against recombinant and native CPA: mixture of rBacCPA250–363H6 and PLC (lane 1), different culture supernatants of C. perfringens CPA protein producers (lane 2–4), and culture supernatant of C. septicum, used as a negative control (lane 5)